Perspective on the current state of the LRRK2 field
Abstract Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-07-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-023-00544-7 |
| _version_ | 1827615109001773056 |
|---|---|
| author | Jean-Marc Taymans Matt Fell Tim Greenamyre Warren D. Hirst Adamantios Mamais Shalini Padmanabhan Inga Peter Hardy Rideout Avner Thaler |
| author_facet | Jean-Marc Taymans Matt Fell Tim Greenamyre Warren D. Hirst Adamantios Mamais Shalini Padmanabhan Inga Peter Hardy Rideout Avner Thaler |
| author_sort | Jean-Marc Taymans |
| collection | DOAJ |
| description | Abstract Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field. |
| first_indexed | 2024-03-09T09:05:28Z |
| format | Article |
| id | doaj.art-ca18d0b49bf042a49e27c3300dadea0f |
| institution | Directory Open Access Journal |
| issn | 2373-8057 |
| language | English |
| last_indexed | 2024-03-09T09:05:28Z |
| publishDate | 2023-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj.art-ca18d0b49bf042a49e27c3300dadea0f2023-12-02T10:35:04ZengNature Portfolionpj Parkinson's Disease2373-80572023-07-01911910.1038/s41531-023-00544-7Perspective on the current state of the LRRK2 fieldJean-Marc Taymans0Matt Fell1Tim Greenamyre2Warren D. Hirst3Adamantios Mamais4Shalini Padmanabhan5Inga Peter6Hardy Rideout7Avner Thaler8Univ. Lille, Inserm, CHU Lille, UMR-S 1172—LilNCog—Lille Neuroscience & CognitionMerck & Co., Inc.Pittsburgh Institute for Neurodegenerative Diseases, University of PittsburghNeurodegenerative Diseases Research Unit, BiogenCenter for Translational Research in Neurodegenerative Disease, Department of Neurology, University of FloridaThe Michael J. Fox Foundation for Parkinson’s Research, Grand Central StationDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount SinaiCentre for Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation of the Academy of AthensMovement Disorders Unit and Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Faculty of medicine, Tel-Aviv UniversityAbstract Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field.https://doi.org/10.1038/s41531-023-00544-7 |
| spellingShingle | Jean-Marc Taymans Matt Fell Tim Greenamyre Warren D. Hirst Adamantios Mamais Shalini Padmanabhan Inga Peter Hardy Rideout Avner Thaler Perspective on the current state of the LRRK2 field npj Parkinson's Disease |
| title | Perspective on the current state of the LRRK2 field |
| title_full | Perspective on the current state of the LRRK2 field |
| title_fullStr | Perspective on the current state of the LRRK2 field |
| title_full_unstemmed | Perspective on the current state of the LRRK2 field |
| title_short | Perspective on the current state of the LRRK2 field |
| title_sort | perspective on the current state of the lrrk2 field |
| url | https://doi.org/10.1038/s41531-023-00544-7 |
| work_keys_str_mv | AT jeanmarctaymans perspectiveonthecurrentstateofthelrrk2field AT mattfell perspectiveonthecurrentstateofthelrrk2field AT timgreenamyre perspectiveonthecurrentstateofthelrrk2field AT warrendhirst perspectiveonthecurrentstateofthelrrk2field AT adamantiosmamais perspectiveonthecurrentstateofthelrrk2field AT shalinipadmanabhan perspectiveonthecurrentstateofthelrrk2field AT ingapeter perspectiveonthecurrentstateofthelrrk2field AT hardyrideout perspectiveonthecurrentstateofthelrrk2field AT avnerthaler perspectiveonthecurrentstateofthelrrk2field |